First, the CSF neurodegenerative biomarkers reach a relatively early plateau shortly before or at the time of the prodromal AD diagnosis (as underlined by publications addressing the putative pathophysiological model of AD) (49), which may alter the representativeness of the respective Aβ and Tau dynamic contributions to earlier AD-related epileptogenesis (as highlighted in animal models) (18, 50). The gene discussed is MAPT; the disease is Alzheimer disease.